My dear Turps,The spelling thing was not directed at you.However...

My dear Turps,

The spelling thing was not directed at you.

However the rest was, as your post to HT was not called for and it was inaccurate on two fronts, 1. The business world is aware of Lux you however are not. 2. You say they have not talked about oxy patch yet the précis says this "Phosphagenics’ first serious pharma product is slated to enter pivotal trials in 2013" if they are not talking about oxy patch then what are they talking about.

Then to ask HT to write a 39 word summary is a bit rich, seems you are always demanding this and that and only offer commentary and never provide your own research. If you think Lux could have done it better then why don't you show us how to do it?

The Lux analysis is extraordinary IMHO. You can't buy a top 5 position out of 1380 companies. Or perhaps you can Turps, do you know for example where the next Australian company is on the list.

We have heard continual carping here by others about the world not knowing about TPM, yet they pop up top 5 on a list of 1380 companies that is a watch list for 2013, and this is not good enough ?

Keep it real folks, you can't have it both ways. Isn't the chairman of Lux a former Pfizer CEO?

Isn't Pfizer the biggest coy in Pharma and Animal Health in the world?

BSW